
INTERVIEW: After Building 165,000 Patients, Empower $CBDT.ca Clinics Sells 1st #CBD Clinic Franchise $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca

North Bud Farms $NBUD.ca Announces Proposed Terms for the Second Tranche of its Non-Brokered Private Placement and Provides a Corporate Update $CGC $ACB $APH $CRON.ca $OGI.ca

- First tranche of the Offering closed on November 6, 2019, at which time the Company issued an aggregate of 1,264 Units for gross proceeds of $1,264,000
- Accordingly, the Company can issue up to an additional $2,736,000 of Units under the Second Tranche
- In the context of a regular follow-up communication with Health Canada, representatives of the Company received verbal feedback that the application review is complete and the reviewers do not have any more questions.
TORONTO, Jan. 27, 2020 – North Bud Farms Inc. (CSE: NBUD) (OTCQB: NOBDF) (“NORTHBUD” or the “Company“) is pleased to announce that it is arranging a closing for the second tranche (the “Second Tranche“) of its non-brokered private placement of 10% secured convertible debenture units (the “Units“) of the Company at a price of C$1,000 for gross proceeds of up to C$4,000,000, originally announced on November 6, 2019 (the “Offering“). The first tranche of the Offering closed on November 6, 2019, at which time the Company issued an aggregate of 1,264 Units for gross proceeds of $1,264,000. Accordingly, the Company can issue up to an additional $2,736,000 of Units under the Second Tranche.
Each Unit issued in connection with the Second Tranche of the Offering is comprised of one C$1,000 principal amount of secured convertible debenture (a “Convertible Debenture“) accruing interest at 10.0% per annum, payable semi-annually in arrears until maturity, and 5,556 common share purchase warrants of the Company (each, a “Warrant“). The Convertible Debentures will have a maturity date of 36 months from the date of issuance. In addition, under the Second Tranche, the Company has the right to prepay an amount equal to the 1st year of interest to be earned by issuing common shares at a deemed price of $0.25 per common share (the “Prepaid Interest Sharesâ€) on the 15th day following the Closing Date should the holders of the Convertible Debentures not elect to receive their 1st year interest paid in cash.
Each Convertible Debenture shall be convertible into common shares in the capital of the Company (each, a “Conversion Share“) at a price of $0.18 (the “Conversion Price“) per Conversion Share.
Each Warrant entitles the holder thereof to acquire one common share in the capital of the Company (each, a “Warrant Share“) for an exercise price of $0.30 per Warrant Share for a period of 36 months following the closing date.
The Convertible Debentures are direct secured obligations of the Company and rank pari passu in right of payment of principal and interest with all other Convertible Debentures issued under the Offering.
Certain directors of the Company have indicated that they may participate in the private placement. Any such purchase would constitute a “related party transaction†within the meaning of Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101â€). The proposed issuance to directors of the Company would be exempt from the formal valuation and minority shareholder approval requirements of MI 61-101 as the fair market value of any Units issued to or the consideration paid by such insiders would not exceed 25% of the Company’s market capitalization.
The Company may pay registered dealers (the “Finders“) a cash commission equal to up to 8% of the aggregate gross proceeds from the sale of the Units sold pursuant to the Offering to eligible investors introduced to the Company by such Finders. In addition, the Company will grant warrants (the “Compensation Warrantsâ€) exercisable at the Conversion Price for a period of 24 months from the Closing Date to acquire in aggregate the number of Common Shares equal to 8% of the gross proceeds under the Offering divided by the Conversion Price.
The proceeds of the Second Tranche will be used by the Company for expansion of the Company’s facilities and for general corporate and working capital purposes.
The Convertible Debentures, Warrants, Prepaid Interest Shares (if any), and any Compensation Warrants issued pursuant to the Second Tranche of the Offering and any common shares in the capital of the Company issued on conversion of the Convertible Debentures or exercise of the Warrants or Compensation Warrants will be subject to a statutory hold period in Canada of four months and one day following the closing date in accordance with applicable securities laws. Additional resale restrictions may be applicable under the laws of other jurisdictions, if any.
The securities of the Company have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act“) or any state securities laws. Accordingly, the securities of the Company may not be offered or sold within the United States unless registered under the U.S. Securities Act and applicable state securities laws or pursuant to an exemption from the registration requirements of the U.S. Securities Act and applicable state securities laws. This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities of the Company in any jurisdiction in which such offer, solicitation or sale would be unlawful.
Amendment to Securities Issued in First Tranche of the Offering
The Company further announces that, in order to ensure equitable treatment of holders, it has decided to amend the terms of the debentures (the “First Tranche Debentures“) and warrants (the “First Tranche Warrants“) issued under the first tranche of the Offering, which closed on November 6, 2019. The Company has amended the First Tranche Debentures to reduce the conversion price to $0.18 per common share and has amended the terms of the First Tranche Warrants to: (a) increase the number of warrants issued per $1000 of principal amount of debenture from 2,000 to 5,556; (b) increase the exercise price from $0.25 to $0.30 per warrant; and (c) extend the expiry date of the warrants from 18 months following the closing date to 36 months following the closing date. The amendments are subject to the final approval of the Canadian Securities Exchange (CSE).
Corporate Update
The Company would also like to provide an update regarding the status of its standard cultivation licence application with Health Canada under the Cannabis Act. In the context of a regular follow-up communication with Health Canada, representatives of the Company received verbal feedback that the application review is complete and the reviewers do not have any more questions. Subject to the re-submission of a required foreign police certificate related to one of the foreign directors of the Company, the Company will be in the final queue for receiving its licence. The Company is confident that it will be able to file the certificate promptly; however, there can be no assurance as to the exact timing of the issuance of the licence by Health Canada or whether the Company will receive any final request from Health Canada.
Further to the Company’s announcement regarding its acquisition of certain California-based businesses on November 22, 2019, the Company has proceeded with the issuance of 1,716,000 common shares, at an issue price of $0.25 per share, to an arm’s length advisor to the Company. The shares, which are subject to a statutory hold period as required by applicable securities laws, are based upon the $429,000 cash value of the 3% M&A fee payable to such advisor in respect of the foregoing California acquisitions.
About North Bud Farms Inc.
North Bud Farms Inc.,
through its U.S. subsidiary Bonfire Brands USA, has acquired cannabis
production facilities in California and in Nevada. The Salinas,
California 11-acre farm is actively cultivating cannabis in its 60,000
sq. ft. of licensed greenhouse production space. The Reno, Nevada
property is located on 3.2-acres of land which was acquired through the
acquisition of Nevada Botanical Science, Inc. a world class cannabis
production, research and development facility with 5,000 sq. ft. of
indoor cultivation which holds medical and adult use licenses for
cultivation, extraction and distribution. Through its wholly owned
Canadian subsidiary, GrowPros MMP Inc., the company is pursuing a
licence under The Cannabis Act, to cultivate in its state-of-the-art
purpose-built cannabis production facility located on 135-acres of
Agricultural Land in Low, Quebec, Canada.
For more information visit: www.northbud.com
Neither the Canadian Securities Exchange (the “CSE“) nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements
Certain statements
included in this press release constitute forward-looking information or
statements (collectively, “forward-looking statements”), including
those identified by the expressions “anticipate”, “believe”, “plan”,
“estimate”, “expect”, “intend”, “may”, “should” and similar expressions
to the extent they relate to the Company or its management. The
forward-looking statements are not historical facts but reflect current
expectations regarding future results or events. This press release
contains forward- looking statements that include, but are not limited
to, statements related to the intended use of proceeds from the
Offering, and the status of the Company’s licence application with
Health Canada under the Cannabis Act. These forward-looking statements
are based on current expectations and various estimates, factors and
assumptions and involve known and unknown risks, uncertainties and other
factors. Such risks and uncertainties include, among others, the risk
factors included in North Bud Farms Inc.’s final long form prospectus
dated August 21, 2018, which is available under the issuer’s SEDAR
profile at www.sedar.com.
FOR ADDITIONAL INFORMATION, PLEASE CONTACT:
North Bud Farms Inc.
Edward Miller
VP, IR & Communications
Office: (855) 628-3420 ext. 3
[email protected]
NORTHBUD $NBUD.ca – Cannabis Industry: 2020 Predictions $CGC $ACB $APH $CRON.ca $OGI.ca
SPONSOR: NORTHBUD (NBUD:CSE) Sustainable low cost, high quality cannabinoid production and procurement focusing on both bio-pharmaceutical development and Cannabinoid Infused Products. Learn More.

Cannabis Industry: 2020 Predictions
- Cannabis Legalization Is Going Global
- Real Medical Testing Will Increase
- Older Customers Will Expand Their Cannabis Purchases Beyond Medical Use
By: Julie Weed Contributor
Here, industry executives predict top trends for 2020.
Cannabis Legalization Is Going Global
Legalization is growing outside of the United States, and countries that are first to the global marketplace can create sustainable advantages for themselves in their customer base and their funding. Kyle Detwiler, chief executive of Clever Leaves, an international operator with brands, extraction facilities, cultivation operations, and other investments in six countries, says that countries like Colombia and Portugal that have been among the first to legalize cannabis “are poised to continue establishing their global dominance in short order.â€
The countries’ first-mover status will also be a magnet for financial interest he said. “There is little doubt that the expanding European cannabis market will make it an attractive investment opportunity,†Detwiler said.
Hemp, the source for CBD in many non-psychoactive products, will expand internationally as well, driven by the CBD’s demand. The CBD market will grow to $2.1 billion in consumer sales by 2020 according to the Hemp Business Journal, with $450 million of those sales coming from hemp-based sources. Puerto Rico’s Department of Agriculture has already reported there will be at least 10,000 acres of hemp cultivated for commercial purposes in 2020
The CBD Product Market Will Mature
CBD is being added to products across the retail spectrum from food to make-up, but with little legal oversight or requirements, the products can easily be mislabeled or ineffective. Clever Leaves chief executive Detwiler says in 2020 CBD standards will begin to emerge based on customer demand. “Consumers are getting more savvy on the benefits of CBD and they will begin to insist on knowing exactly what they are paying for and what they are getting when they purchase ‘CBD’,†Detwiller said.
Consumers will “begin to insist†on CBD standards agrees Bill Thurman, chief executive of Redbird Bioscience a medical cannabis operator and producer of pharmaceutical-grade cannabis for patients in Oklahoma.
Thurman said companies will help the market succeed as a whole if they adhere to high quality standards and agreed-upon guidelines in testing and manufacturing. That kind of rigor is needed to significantly increase the size of the market and only by conducting “science-driven randomized clinical studies, can we shed reliance on anecdotal data to support medical claims,†he said.
Barbara Goodstein of B GREAT which produces full-spectrum upscale CBD items expects CBD to be added to even more products like deodorant, hand soaps, throat sprays and nasal sprays. The popularity of the category also creates additional business risks according to Goodstein. “The hype around this space will end up creating applications and uses that make no sense, which will unfortunately diminish the real value of the product,†she said.
Real Medical Testing Will Increase
Until cannabis is taken of the Schedule One substance list, medical research will be challenging to undertake. Still, executives in the industry are seeing some movement in the area. Israel still leads the world in global cannabis research, and Israeli scientists like chemist Raphael Mechoulam, a researcher at Hebrew University and pioneer in cannabis research, are being hired or given research grants by American organizations.
Dr. William Levine, founder and chief scientific officer of CannRx a subsidiary of Izun Pharmaceuticals that develops proprietary medical and recreational products expects companies to use better data, and well-designed clinical trials. His own company is focused on better “bio-availability†which focuses on lower dose products that can offer similar benefits to higher dose products, but with fewer side effects.
Older Customers Will Expand Their Cannabis Purchases Beyond Medical Use
CannRx’s Levine predicts there will be “increased recreational expansion into older populations,†as product quality and more controlled dosing options come to market.
Legislative Action Will Remain Robust
According to Marijuana Moment, as of January 16, there were 975 cannabis-related bills moving through state legislatures and Congress for 2020 sessions.
“We expect to see a lot more regulatory activity in 2020 on both the state and federal levels,†said Redbird Bioscience’s Thurman.
Each state makes its own rules. For example, regarding medical marijuana use, some states have a list of specific ailments that can warrant a recommendation of the substance (states include Florida and New Jersey). In other states the decision to use medical marijuana is entirely between patient and doctor (states include Oklahoma and California.)
States will have more models to look to as they develop their laws and will likely start adopting each others’ best practices. Law makers will start learning more from each other’s experiences and “harmonize†their regulations with each other said Levine. He also believes the federal government could take the first step to legalize medical marijuana.
Matt Anderson, chief executive of Vanguard Scientific, a company that provides service resources for cannabis and hemp botanical extraction, says just the ongoing discussion of legalization and decriminalization will continue to drive market growth.
Multi-state Operators Will Face A Shake-out
Running a cannabis business is expensive, and running a multi-state cannabis business when each state has its own rules to abide by make it hard to achieve economies of scale. Lack of access to traditional sources of capital like debt and equity add to the challenge. This year will see a few multi-state operators (MSOs) fold and sell off their component companies according to Lewis Goldberg, managing partner of KCSA Strategic Communications“
Most of the MSOs have been run by financial operators Goldberg said, not operational experts, but “with the need to deliver results, that will change.â€
Back To Basics
Businesses are focusing on the fundamentals to stay solvent or to make themselves attractive acquisition targets. Matt Hawkins, chief executive of Entourage Effect Capital a cannabis-only private-equity firm that has deployed more than $50 million into 32 companies says companies will “make every effort to be more efficient.†They will still aggressively seek out new customer bases and explore innovation, he said, “but preserving margins will matter.â€
Jeff Fallows, president of The Valens Company, says he also expects to see a marked improvement in the underlying fundamentals of the companies themselves. This will be a big year for the companies that execute well on their business plans, he said. Those companies will “emerge as leaders and those will be the ones to watch in 2020 and beyond. “
Source: https://www.forbes.com/sites/forbestreptalks/2020/01/26/cannabis-industry-2020-predictions/#87768c3f31ff
Goodyear To Launch Bicycle Tires With Graphene Technology SPONSOR Gratomic $GRAT.ca $SRG.ca $NGC.ca $LLG.ca $GPH.ca $NOU.ca #TODAQ

SPONSOR: Gratomic Inc. (TSX-V: GRAT) Advanced materials company focused on mine to market commercialization of graphite products, most notably high value graphene based components for a range of mass market products. Collaborating with Perpetuus, Gratomic will use Aukam graphite to manufacture graphene products for commercialization on an industrial scale. For More Info Click Here
- Goodyear developed a proprietary compound enhanced with graphene
- The rubber is able to deliver low rolling resistance, improved grip in the dry and wet and long-term durability.
Famous tire and rubber company Goodyear has launched two new bicycle tyres, Eagle F1 and Eagle F1 Supersport utilizing graphene technology and weighing just 180g for a 23mm model.

The new Eagle F1 is an “ultra-high-performance all-round road tire†and the Eagle F1 Supersport, which is even lighter, is aimed at the upper echelons of competition and will be suited to road racing, time trial and triathlon where speed trumps all other requirements.
In the tire world, Vittoria has become well-known for adding the wonder material to its tires for several years, and Goodyear has followed suit with its new rubber compound.
Goodyear has developed a proprietary compound enhanced with graphene and “next-generation amorphous (non-crystalline) spherical Silica†to create what it labels Dynamic:GSR. The result of this is said to be a rubber that is able to deliver low rolling resistance, improved grip in the dry and wet and long-term durability.
he Eagle F1 comes in five width options from 23 to 32mm, while the Eagle F1 Supersport comes in three widths from 23 to 28mm.
To produce the new tire Goodyear has invested in its own factory in Taiwan and has developed a process that allows much greater control over the construction of the tire. It didn’t share too many details, but it believes this enhanced precision contributes to significant weight savings.
Currently the new Eagle F1 and F1 Supersport are only available as clincher tube-type tires, but a tubeless tire is reportedly in the pipeline for a launch later this year.
The new tires will cost from £45 and be in shops in February.
SOURCE: https://www.graphene-info.com/goodyear-launch-bicycle-tires-graphene-technology
Researchers Develop A New Technique for Making Graphene Oxide and Implement it in Improved Supercapacitors SPONSOR – ZEN Graphene Solutions $ZEN.ca $LLG.ca $FMS.ca $NGC.ca $CVE.ca $DNI.ca

SPONSOR: ZEN Graphene Solutions: An emerging advanced materials and graphene development company with a focus on new solutions using pure graphene and other two-dimensional materials. Our competitive advantage relies on the unique qualities of our multi-decade supply of precursor materials in the Albany Graphite Deposit. Independent labs in Japan, UK, Israel, USA and Canada confirm this. Click here for more information

Researchers at the India-based Central Mechanical Engineering Research Institute (CMERI) are developing an economical graphene-based supercapacitor that can present an effective alternative to providing energy to various applications, including state-of-the-art military equipment, mobile devices and modern vehicles.
Graphene has been used in the newly developed ultra-capacitors to replace the expensive activated carbon, and the switch seems to have also reduced the supercapacitors’ weight and cost by ten times.
The team has developed a new technique for making graphene oxide, which is being used to produce new ultra-capacitors.
CMERI scientist Dr. Naresh Chandra Murmu stated that “scientists have developed a technique for producing graphene oxide. The production cost of one kilogram of graphene oxide using this technique comes to around ten thousand rupees, which is much lesser than the cost of activated carbon used in supercapacitors. We have modified the surface of graphene oxide in our research, due to which it has also succeeded in reducing its weight. We have now reached the advanced stage of making ultra-capacitors by using this graphene oxide, which can be useful in various sectors.â€
Former Senior Defense Development Research Organization (DRDO) official M.H. Rahman said that such devices not only cater to civilian applications, but can be applicable in strategic and defense applications as well.
SOURCE: https://www.graphene-info.com/researchers-develop-new-technique-making-graphene-oxide-which-they-use-improving
Applied BioSciences $APPB: Innovative CBD System Balancing $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

SPONSOR: Applied BioSciences is a vertically integrated company focused on the development and commercialization of novel, science-driven, synthetic cannabinoid therapeutics / biopharmaceuticals; targeting the endocannabinoid system to treat a wide-range of diseases across multiple therapeutic areas. Click Here for More Info

All cannabidiol (CBD) is not created equal in clinical practice in terms of implementation. The most frustrating thing for clinicians and also for patients is when an intended protocol doesn’t work. As I discuss later under the “With treatment, start low†section of this article, there are ways to use CBD most effectively.
You probably weren’t taught this in medical school, but CBD works on the endocannabinoid system (ECS). The ECS contains CB1 and CB2 receptors, in addition to other receptors that are activated by the naturally occurring endocannabinoids made in our bodies, called anandamide and 2-AG. We all have CB1 or CB2 receptors within our body — if you have a cat or dog, they have these receptors too. All mammals do. How could it be that we did not even know of the predominance of the ECS until 1992?
What the endocannabinoid system can do
Patients coming in worn out can be a sign of endocannabinoid deficiency and the inability to support their pathways optimally, much like adrenal fatigue. Phytocannabinoids like CBD obtained from hemp products can act on the same receptors as endocannabinoids made in the body. CBD receptors, much like opioid receptors, control pain, but via a different mechanism.
Patients arrive at our clinical practices fatigued, anxious, in pain, inflamed, and lots reach a point of adrenal burnout, adrenal fatigue. Indeed, that is often the case because they are suffering from an endocannabinoid deficiency. We see people who have low adrenal function at noon, and in the evening, they are tired, dragging, eat lunch, get a little spike, and then they start free falling again. They’re flat-lining. How is it that we wake up each morning anticipating with trepidation and run with go, go, go pace and finish the day glad to have survived another day? Life is meant for more than that; it is time to shift our goals from merely surviving to thriving mode!
Researchers observed approximately six years ago that people were more anxious and depressed in the middle of the summer than ever before, a new phenomenon. This goes against what we previously believed, that depression spiked mostly in the holiday season and Thanksgiving and after the winter solstice. But now we’re seeing people are worn out even in summer. Indeed, the endocannabinoid system plays a role here.
Anandamide is one of our endocannabinoids. When it becomes lower, patients are more anxious. There is less healing of the brain, less neurogenesis, and the hypothalamic-pituitary axis is triggered, causing a whole cascade of events to occur. What we now know is that the endocannabinoid system naturally, or with the use of CBD, alters our microbiome in our gut, beneficially affecting the gut-brain axis. The GI tract is the site of many receptors. We make about 70% of our serotonin, the happy-brain chemical, in the GI tract. About 70-80% of our immune system is in our GI tract, so is it any surprise that we have CB1, CB2 regulatory pathways in our GI tract that work via the endocannabinoid system to control inflammation? These same pathways can be regulated using an innovative CBD strategy.
Migraines and the endocannabinoid system
With endocannabinoid deficiency symptoms patients can get migraines. We thought migraines were just triggered by tyramine-rich foods, such as cheese, fermented foods, and salami and other such foods; along with other triggers as well.
However, the endocannabinoid pathway is designed to control pain and inflammation and also regulate the immune system to a large degree. I have found in my clinical practice that innovative CBD strategies can be useful in supporting the health of migraine sufferers.
Treat the brain, treat the pain
The body is designed with innate intelligence to sustain optimal
performance. People ask, “Well, how is CBD metabolized?†It’s primarily
metabolized through the liver, and as a result, it goes through the
cytochrome 450 and other pathways.
Wellness is ultimately about
homeostasis. We all know the term entropy, the tendency for the universe
to move toward chaos. But our body exerts a phenomenal amount of energy
to maintain order and wellness. However, if the endocannabinoid system
becomes deficient, this will adversely affect wellness. This
endocannabinoid deficiency, in turn, affects the microbiome,
contributing to a less healthy endocannabinoidome.
CBD can conserve anandamide that is made by the body, and CBD can support anandamide conservation in an attempt to bring the body back into homeostasis. The endocannabinoid system supports brain health. By treating the brain, it addresses the pain, because if we didn’t have a brain, we wouldn’t feel the pain from a perception perspective.
Anxiety also is a biochemical process. It’s real. A lot of people say, “It’s all in my head.†No, stress is real because it’s a physiological effect. There is biochemistry involved in anxiety. We want to use innovative CBD strategies to support calming pathways and bring peace and harmony into the brain.
Endocannabinoid deficiency issues
If a patient has brain inflammation, neuroplasticity is not going to be as healthy or robust. And the fact is, on a typical day, we lose about 86,400 brain cells. CBD is an anti-inflammatory application. And from a neuropathic perspective, activation of cannabinoid receptors is essential. I’ve looked at research involving the endocannabinoid system relative to cancer medications and so forth. Not being an oncologist, I am not suggesting this is a treatment for cancer, but there are pain, stress and immune challenges that often need to be associated with this disease state, so visiting with one’s provider in this arena is vital.
We can start manifesting symptoms of migraines, fatigue, irritable bowel, whatever it might be, as a result of being subpar, insufficient or deficient of endocannabinoids. An endocannabinoid deficiency manifests itself as simply that the body has gotten worn down, much like low adrenal function, often called adrenal fatigue. So we need to support that pathway to bring it back on track like we would any other functional biochemistry, which our body is designed to do. And since we’re designed to make endocannabinoids, we need to bring those levels back up to par.
With treatment, start low
The goal is to start low and go slow, as a little bit can go a long way for many patients. More is not always better, as each person responds differently based on genetics, biochemistry and individual need.
Just like if you’re performing an adjustment, a little bit of a movement might get the job done. Work with gentle modulation of the endocannabinoid system. You’re working within the innate ability of the body.
Fifteen to 25 milligrams per day is what I start my patients on. In a week or two, if I need to move them up to 25 mg two to three times a day, I will. Once again, if a little bit gets the job done, why more? It is of paramount importance to respect the innate delicate balance physiology of the body. Some patients will need much higher doses because of their endocannabinoid insufficiency or potential genetic polymorphisms. You’re going to encounter genetic polymorphisms, or what I termed mutations of the CBD receptors and the CBD pathway.
I never go to high-milligram doses, especially on patients taking pharmaceutical drugs, without working with their pharmacists, because CBD can affect similar liver detoxification, as well as other biochemical pathways of how drugs are metabolized, much like grapefruit juice, can impact many of the same medications. We want to also support those drug-metabolizing pathways with diet and lifestyle.
CBD, when dosed properly, can positively supplement a health-promoting diet and lifestyle. It’s not a substitute for these things. So, we want to ensure we’re taking steps to support the body at a foundational level. Additionally, we always want to ensure the THC levels in the CBD you are using are less than 0.3%, or that the CBD contains no THC, when targeting hemp-derived CBD.
We all get broken or get older
Endocannabinoid deficiency is associated with low cortisol, stress and adrenal fatigue. We’re all getting older. Our mitochondria are wearing down. Our nitric oxide levels aren’t as robust as they used to be, and we need support at a fundamental level. In regards to the 65 potential molecular targets that are currently known for CBD, there is a lot of untapped potential here relative to stress and aging. Innovative CBD use is a new area; it can be a scary area, but remember, our bodies have been producing endocannabinoids for millennia. All we’re doing is supporting a natural pathway.
source: https://www.chiroeco.com/innovative-cbd/
Discerning fake or deceptive stories has become increasingly difficult over the last four years American Citizens say – SPONSOR: Datametrex AI Limited $DM.ca
SPONSOR: Datametrex AI Limited (TSX-V: DM) A revenue generating small cap A.I. company that NATO and Canadian Defence are using to fight fake news & social media threats. The company announced three $1M contacts in Q3-2019. Click here for more info.

Discerning fake or deceptive stories has become increasingly difficult over the last four years American Citizens say
- New polls found that 59 percent of Americans state it is difficult to recognize bogus data, deliberately deceptive and incorrect stories depicted as truth, via web-based networking media
- Another 37 per cent deviated, saying it is anything but difficult to spot
by nitin198
Four years after Russia propelled a digital campaign to upset and impact the 2016 presidential crusade, about 33% of Americans state deceiving stories via web-based networking media represent the greatest risk to the wellbeing of U.S. elections. Half of the population thinks President Trump encourages political race impedance, as indicated by the most recent PBS NewsHour/NPR/Marist survey.
A larger part of the American populace says detecting the distinction among certainty and bogus data via web-based networking media is troublesome and gotten more prominent since 2016. Hardly any vibe assures them that tech companies will forestall the abuse of social media to impact the upcoming 2020 elections.
Is misinformation getting more difficult to spot?
The new polls found that 59 percent of Americans state it is difficult to recognize bogus data, deliberately deceptive and incorrect stories depicted as truth, via web-based networking media. Another 37 per cent deviated, saying it is anything but difficult to spot.
Moreover, with the 2020 presidential battle about to get going vigorously, the greater part of U.S. grown-ups said recognizing these phony or misleading stories has gotten progressively troublesome in the course of the most recent four years. That conclusion was shared by 58 per cent of Democrats, 55 per cent of independents and a somewhat lower extent of Republicans at 44 per cent.
The fact that Americans know about the risk of deception is significant. However, it is nonsensical to anticipate that a normal individual should truth check each snippet of data zooming past them as they look through their online networking feeds.
Research has indicated that bogus data disperses quicker than reality via social media. In 2018, an investigation from the Massachusetts Institute for Technology said deception moved multiple times quicker than the reality on Twitter.
Who does the public depend on to be truth’s guardian?
39 per cent of Americans state the news media is liable for reviewing deceiving data. Another 18 per cent state that organizations like Facebook, Twitter or Google are capable. Furthermore, 15 per cent state the government’s essential occupation is to diminish the public’s presentation to deception.
Are the web-based social networking organizations doing what’s needed?
Seventy-five per cent of U.S. grown-ups have little trust in Facebook, Twitter, Google, and YouTube to stop the spread of falsehood. Just 5 per cent of survey responders said they felt “extremely sure†these organizations would forestall the viral spread of bogus stories.
The populace lacks trust in significant social media organizations, notwithstanding tech goliaths; for example, Facebook and Twitter have vowed to find a way to forestall election impedance on their platforms. Facebook, one of the most famous social media platforms, has said it will make a superior showing of expelling deceiving political promotions before the 2020 presidential political decision. Twitter said it will boycott political advertisements inside and out.
Americans are wary that social media organizations will respect these guarantees. Americans additionally realize platforms aren’t doing what’s necessary to stop the spread of falsehood. In May 2018, Facebook made a political promotion file to distinguish and research possibly hazardous advertisements; however, that mechanized framework isn’t immaculate.
Source: https://techsprouts.com/discerning-fake-or-deceptive-stories-has-become-increasingly-difficult-over-the-last-four-years-american-citizens-say/
The Top 5 Tech Trends That Will Disrupt Education In 2020 – The #EdTech Innovations Everyone Should Watch SPONSOR: BetterU Education Corp. $BTRU.ca $ARCL $CPLA $BPI $FC.ca
| SPONSOR: BetterU Education Corp. aims to provide access to quality education from around the world. The company plans to bridge the prevailing gap in the education and job industry and enhance the lives of its prospective learners by developing an integrated ecosystem. Click here for more information. |

The Top 5 Tech Trends That Will Disrupt Education In 2020 – The EdTech Innovations Everyone Should Watch
Bernard Marr ContributorÂ
- One solid indicator that EdTech is big business is the number of billionaires the sector created.
- According to Deloitte, the Chinese education market should reach $715 billion by 2025 and was responsible for creating seven new billionaires.
The richest was Li Yongxin, who leads Offcn Education Technology that provides online and offline training for individuals who want to take civil service exams, but there were other EdTech business leaders represented. Here we consider the key technologies that underpin the EdTech revolution as well as the top 5 tech trends set to disrupt education in 2020.

Key Technologies that Underpin the EdTech Revolution
A discussion about the top tech trends that will disrupt education must first begin with the technologies that will influence these trends.
Artificial intelligence will continue to fill gaps in learning and teaching and help personalize and streamline education. As students interact with connected Internet of Things (IoT) devices and other digital tools, data will be gathered. This big data and analysis of it is instrumental for personalized learning, determining interventions, and what tools are effective. Extended reality, including virtual, augmented, and mixed realities, helps create different learning opportunities that can engage students even further. Education is increasingly becoming mobile, and educational institutions are figuring out ways to enhance the student experience by implementing mobile technology solutions. Of course, this technology requires a capable network to handle the traffic demands, and 5G technology will provide powerful new mobile data capabilities. Finally, blockchain technology offers educational institutions to store and secure student records.
Top 5 Tech Trends That Will Disrupt Education in 2020
1. More accessible education
There aren’t only financial considerations when speaking about how accessible education is. The UN estimates there are more 263 million kids globally who are not getting a full-time education. While there are many reasons for this statistic, such as access to a qualified educational facility, there are also issues with proper materials, learning accommodations, and more. Online learning makes education available to those even in remote areas as well as make it easy to share curriculum across borders. EdTech solutions can overcome many common barriers to a quality education.
Technology can improve access to education. Digital textbooks that can be accessed online 24/7 won’t require transportation to get to an educational facility or library during certain hours. Digital copies are relatively cheap to produce, so textbook fees aren’t as taxing for digital versions as they might be with physical versions that cost more to create. Similarly, translating physical textbooks into all the languages natively spoken is cost-prohibitive for publishers when they are producing only physical copies of books. Digital versions make these translations much more feasible.
Within the classroom, the ultimate accommodation for learning differences is called differentiated learning. This allows students to have learning that is tailored to their personal needs. This and student-paced learning where students can move through and review material at the speed they need is much more feasible when using technology. There are also tech solutions for students who have physical or learning disabilities.
2. More data-driven insights
Just like it does for other industries, technology can help educational institutions and educators be more effective and efficient. By analyzing the data about how digital textbooks are consumed, or educational technology is used, valuable data-driven insights for how to enhance learning can be attained as well as provide info to make decisions about what tools aren’t effective. Technology, including big data, machine learning, and artificial intelligence, will also allow for more in-depth personalization of the content for an individual’s learning needs. At the university level, data is no longer siloed into individual department’s Excel spreadsheets but is consolidated at the institution level, so insights can be extracted. With the assistance of data-driven insights to readily see where students need more support and what support is necessary, teachers are freed up to inspire students and change lives.
3. More personalized education
While a personalized education experience isn’t a novel concept, technology can make achieving it much easier. Today’s classrooms are diverse and complex, and access to technology helps better meet each student’s needs. Technological tools can free teachers up from administrative tasks such as grading and testing to develop individual student relationships. Teachers can access a variety of learning tools through technology to give students differentiated learning experiences outside of the established curriculum.
4. More immersive education
Extended reality encompassing virtual, augmented, and mixed reality brings immersive learning experiences to students no matter where they are. A lesson about ancient Egypt can literally come alive when a student puts on a VR headset and walks around a digital version of the time period. Students can experience hard-to-conceptualize current-day topics through extended reality, such as walking among camps of Syrian refugees. This technology enables learning by doing. Students are used to using voice interfaces at home when asking Alexa to define a word when doing homework, but this technology can also support learning and improve education in other ways. Chatbots can deliver lectures via conversational messages and engage students in learning with a communication tool they have become quite comfortable with, such as what CourseQ offers. Ultimately, if chatbots can make the learning process more engaging for students and reduce the workload on human educators, their use in education will continue to grow.
5. More automated schools
Many schools already rely on online assessments that are flexible, interactive, and efficient to deliver. Automation will continue to alter schools as more smart tools get incorporated, including face recognition technology to take attendance, autonomous data analysis to inform learning decisions so teachers don’t need to analyze data as well as help automate administrative tasks. When a student interacts with online technology, they leave a digital footprint that informs learning analytics. But automation will also help control building costs by automatically controlling lighting and heating/cooling systems and to help keep students safe with automated school security systems.
Source: https://www.forbes.com/sites/bernardmarr/2020/01/20/the-top-5-tech-trends-that-will-disrupt-education-in-2020the-edtech-innovations-everyone-should-watch/#5dbc43f42c5b
